The round
Nanopath announced a Series B round of $25M on November 10, 2026, led by Norwest, SV Health Investors MedTech Convergence Fund. Other participants include Labcorp Venture Fund, Elderberry Ventures, GingerBread Capital, Alumni Ventures.
The Signal$25 million financing package includes $2 million in non-dilutive grants; it is not $25 million of equity plus grants. Nanopath announced a $25 million Series B financing package on November 10, 2026, including $2 million in non-dilutive grants. Norwest and SV Health Investors' MedTech Convergence Fund co-led, with Labcorp Venture Fund participating. The financing supports manufacturing and initiation of an FDA 510(k) clinical study for a 15-minute vaginitis assay. The assay is under development and has not been FDA cleared or approved. Alison Burklund, PhD and Amogha Tadimety, PhD are co-founders and co-CEOs.
What Nanopath does
Optical biosensing for molecular testing at the point of care.
Nanopath announced a $25 million Series B financing package on November 10, 2026, including $2 million in non-dilutive grants. Norwest and SV Health Investors' MedTech Convergence Fund co-led, with Labcorp Venture Fund participating. The financing supports manufacturing and initiation of an FDA 510(k) clinical study for a 15-minute vaginitis assay. The assay is under development and has not been FDA cleared or approved. Alison Burklund, PhD and Amogha Tadimety, PhD are co-founders and co-CEOs.
Full Nanopath profile- Company
- Nanopath
- Amount
- $25M
- Stage
- Series B
- Announced
- November 10, 2026
- Led by
- Norwest, SV Health Investors MedTech Convergence Fund
- Other investors
- Labcorp Venture Fund, Elderberry Ventures, GingerBread Capital, Alumni Ventures
- Vertical
- Women's Health
- Headquarters
- Cambridge, Massachusetts, United States
- Founded
- 2020